Immuno-Oncology With Mass Cytometry
Emerging Approaches to Improving Adoptive Cell Therapy
Flow cytometry with CyTOF® is enabling improved profiling of CAR (chimeric antigen receptor) cell products and their functional characteristics.
The use of CAR cells as therapeutic agents in cancer is expanding at a rapid pace, but significant challenges remain. Investigators are taking innovative approaches to address these challenges.
The expert research shared here spans diverse aspects of CAR cell therapeutic development, from expanding our understanding of immune cell function to improving CAR T manufacturing to monitoring CAR cells in clinical research trials.
» Contact us for more info.
» Learn more about immune profiling with CyTOF.
WEBINARS
Expanding CAR T Cell Profiling to Accelerate Therapeutic Insights
Greg Hopkins
Associate Manager, Scientist, 2seventy bio™
Understanding the Metabolic Dynamics of T Cells and CAR T Cells From Single-Cell Data
Matthew Spitzer, PhD
Assistant Professor, University of California San Francisco (UCSF)
Mass Cytometry: A Robust Platform for the Comprehensive Immunomonitoring of CAR T Cell Therapies
Jonathan Caron, PhD
Researcher, Assistance Publique – Hôpitaux de Paris
Customer Stories
Learn more about how our customers are leveraging Standard BioTools technology
VIEW ALLKara Davis, DO
Predicting relapse in childhood leukemia and expanding therapy options
Evan Newell, PhD
Evan Newell on decoding immune cell heterogeneity with mass cytometry
Wendy Fantl, PhD
On the right path to better ovarian cancer diagnosis and treatment
No CyTOF? No problem!
We can help you convert your fluorescence panel and find a service provider.
For Research Use Only. Not for use in diagnostic procedures. Patent and License Information: www.standardbio.com/legal/notices. Trademarks: www.standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. All rights reserved.